Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eisai CoESALF 69 EV-to-EBIT is 19.01 as of Jul. 16, 2026, which is 107% above its 10-year median of 9.18. GuruFocus rates ESALF with a GF Score™ of 69/100 and a GF Value™ of $35.08 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 687 Drug Manufacturers companies, Eisai Co ranks worse than 59.97% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Eisai Co's Enterprise Value for the quarter that ended in Mar. 2026 was $8,242 Mil.
Eisai Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $379 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co EV-to-EBIT Related Terms
Eisai Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Eisai Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Eisai Co's EV-to-EBIT falls into.
Eisai Co's current Enterprise Value is $7,214 Mil.
Eisai Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $379 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESALF) has a EV-to-EBIT of 19.01 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eisai Co and its competitors. This is 107% above median its historical median of 9.18. According to the industry distribution chart, Eisai Co ranks #412 out of 687 companies in the Drug Manufacturers industry, placing it in the top 60%.
Is Eisai Co's EV-to-EBIT too high?
Eisai Co's current EV-to-EBIT of 19.01 is 107% above median its 10-year median of 9.18. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Eisai Co's value of 19.01 is 19.9% above this industry median. Based on the distribution chart, Eisai Co ranks #412 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #412 out of 687 companies for EV-to-EBIT. This places Eisai Co in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Eisai Co's value of 19.01 is 19.9% above this benchmark. While the company's 10-year median is 9.18 vs. the industry median of 15.86, Eisai Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current EV-to-EBIT of 19.01 is 19.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current EV-to-EBIT is 19.01, which is 107% above median its own 10-year median of 9.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.08, compared to a current price of $26.18 — trading 25.4% below its estimated fair value. The current EV-to-EBIT is 19.01, which is 107% above median its 10-year median of 9.18 and 19.9% above the Drug Manufacturers industry median of 15.86. Eisai Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Eisai Co (ESALF), the current EV-to-EBIT is 19.01 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $26.18 is trading 25.4% below its estimated GF Value™ of $35.08.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
EV-to-EBIT: 19.01 (107% above median its 10-year median of 9.18)
GF Value™: $35.08 vs. price of $26.18 (25.4% below fair value)
Industry Position: 19.9% above the Drug Manufacturers median (#412 of 687)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for ESALF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
